Cellect Biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration. Achieving higher selectivity, greater specificity and decreased toxicity, Cellect envisions its products becoming an integral and essential part of Bone Marrow Transplantation (BMT), as well as integrated into many aspects of regenerative medicine.
The Company’s first product line is designed to eliminate the risk of Graft versus Host Disease (GVHD), a common, life threatening, complication that constitutes the main drawback of BMT. Elimination of potentially detrimental cellular constituents was found to reduce dramatically adverse events of BMT while high success rates can be maintained. This effect is achieved by in-vitro functional selection of beneficial Hematopoietic stem cells over mature cells available in the sample, maintaining only the cells needed for engraftment and anti-tumor effects while discarding those responsible for rejection and GVHD.
Once proof of concept in humans is achieved, the Company intends to expedite development of its portfolio products through international alliances, and co-development programs.